Terms: = Breast cancer AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809 AND Clinical Outcome
30 results:
1. Two-Dimensional-PAGE Coupled with nLC-MS/MS-Based Identification of Differentially Expressed Proteins and Tumorigenic Pathways in MCF7 breast cancer Cells Transfected for JTB Protein Silencing.
Jayathirtha M; Jayaweera T; Whitham D; Sullivan I; Petre BA; Darie CC; Neagu AN
Molecules; 2023 Nov; 28(22):. PubMed ID: 38005222
[TBL] [Abstract] [Full Text] [Related]
2. TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer.
Gu Y; Gao H; Zhang H; John A; Zhu X; Shivaram S; Yu J; Weinshilboum RM; Wang L
Oncogene; 2022 Aug; 41(35):4119-4129. PubMed ID: 35864174
[TBL] [Abstract] [Full Text] [Related]
3. A concise review on the role of BDNF-AS in human disorders.
Ghafouri-Fard S; Khoshbakht T; Taheri M; Ghanbari M
Biomed Pharmacother; 2021 Oct; 142():112051. PubMed ID: 34426254
[TBL] [Abstract] [Full Text] [Related]
4. Dynamic changes of CTCs in patients with metastatic HR(+)/HER2(-) breast cancer receiving salvage treatment with everolimus/exemestane.
Spiliotaki M; Kallergi G; Nikolaou C; Xenidis N; Politaki E; Apostolaki S; Georgoulia N; Koinis F; Tsoukalas N; Hatzidaki D; Kotsakis A; Georgoulias V
Cancer Chemother Pharmacol; 2021 Feb; 87(2):277-287. PubMed ID: 33515073
[TBL] [Abstract] [Full Text] [Related]
5. Everolimus-Related Pneumonitis in Patients with Metastatic breast cancer: Incidence, Radiographic Patterns, and Relevance to clinical outcome.
Gong C; Xiao Q; Li Y; Gu Y; Zhang J; Wang L; Cao J; Tao Z; Zhao Y; Xie Y; Hu X; Wang B
Oncologist; 2021 Apr; 26(4):e580-e587. PubMed ID: 33191524
[TBL] [Abstract] [Full Text] [Related]
6. Imatinib revives the therapeutic potential of metformin on ewing sarcoma by attenuating tumor hypoxic response and inhibiting convergent signaling pathways.
Nan X; Wang J; Cheng H; Yin Z; Sheng J; Qiu B; Lau CC; Yustein JT; Zhao H; Wong STC
Cancer Lett; 2020 Jan; 469():195-206. PubMed ID: 31672491
[TBL] [Abstract] [Full Text] [Related]
7. Molecular characterization of metaplastic breast carcinoma via next-generation sequencing.
Zhai J; Giannini G; Ewalt MD; Zhang EY; Invernizzi M; Niland J; Lai LL
Hum Pathol; 2019 Apr; 86():85-92. PubMed ID: 30537493
[TBL] [Abstract] [Full Text] [Related]
8. Downregulation of MCL-1 and upregulation of PUMA using mtor inhibitors enhance antitumor efficacy of BH3 mimetics in triple-negative breast cancer.
Li H; Liu L; Chang H; Zou Z; Xing D
Cell Death Dis; 2018 Jan; 9(2):137. PubMed ID: 29374168
[TBL] [Abstract] [Full Text] [Related]
9. Torin2 enhances the radiosensitivity of MCF‑7 breast cancer cells by downregulating the mtor signaling pathway and ATM phosphorylation.
Luo J; Pi G; Xiao H; Ye Y; Li Q; Zhao L; Huang H; Luo H; Zhang Q; Wang D; Wang G
Mol Med Rep; 2018 Jan; 17(1):366-373. PubMed ID: 29115478
[TBL] [Abstract] [Full Text] [Related]
10. High expression of endoglin in primary breast cancer may predict response to neoadjuvant chemotherapy.
Rau KM; Su YL; Li SH; Hsieh MC; Wu SC; Chou FF; Chiu TJ; Chen YH; Liu CT
Mol Med Rep; 2017 Nov; 16(5):7185-7190. PubMed ID: 28944897
[TBL] [Abstract] [Full Text] [Related]
11. Glycogen synthase kinase-3 inhibition sensitizes human induced pluripotent stem cells to thiol-containing antioxidants induced apoptosis.
Tu C; Xu R; Koleti M; Zoldan J
Stem Cell Res; 2017 Aug; 23():182-187. PubMed ID: 28772167
[TBL] [Abstract] [Full Text] [Related]
12. Exceptional durable response to everolimus in a patient with biphenotypic breast cancer harboring an
Parachoniak CA; Rankin A; Gaffney B; Hartmaier R; Spritz D; Erlich RL; Miller VA; Morosini D; Stephens P; Ross JS; Keech J; Chmielecki J
Cold Spring Harb Mol Case Stud; 2017 Sep; 3(5):. PubMed ID: 28550065
[TBL] [Abstract] [Full Text] [Related]
13. The Therapeutic Potential of PI3K/Akt/mtor Inhibitors in breast cancer: Rational and Progress.
Bahrami A; Khazaei M; Shahidsales S; Hassanian SM; Hasanzadeh M; Maftouh M; Ferns GA; Avan A
J Cell Biochem; 2018 Jan; 119(1):213-222. PubMed ID: 28513879
[TBL] [Abstract] [Full Text] [Related]
14. PI3K-AKT-mtor inhibitors in breast cancers: From tumor cell signaling to clinical trials.
Dey N; De P; Leyland-Jones B
Pharmacol Ther; 2017 Jul; 175():91-106. PubMed ID: 28216025
[TBL] [Abstract] [Full Text] [Related]
15. A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing breast cancer.
Menyhárt O; Santarpia L; Győrffy B
Curr Cancer Drug Targets; 2015; 15(8):665-83. PubMed ID: 26452383
[TBL] [Abstract] [Full Text] [Related]
16. Denoising perturbation signatures reveal an actionable AKT-signaling gene module underlying a poor clinical outcome in endocrine-treated ER+ breast cancer.
Teschendorff AE; Li L; Yang Z
Genome Biol; 2015 Apr; 16(1):61. PubMed ID: 25886003
[TBL] [Abstract] [Full Text] [Related]
17. The mechanistic target for rapamycin pathway is related to the phosphorylation score for estrogen receptor-α in human breast tumors in vivo.
Shrivastav A; Bruce M; Jaksic D; Bader T; Seekallu S; Penner C; Nugent Z; Watson P; Murphy L
Breast Cancer Res; 2014 May; 16(3):R49. PubMed ID: 24887419
[TBL] [Abstract] [Full Text] [Related]
18. Temsirolimus and pegylated liposomal doxorubicin (PLD) combination therapy in breast, endometrial, and ovarian cancer: phase Ib results and prediction of clinical outcome with FDG-PET/CT.
Boers-Sonderen MJ; de Geus-Oei LF; Desar IM; van der Graaf WT; Oyen WJ; Ottevanger PB; van Herpen CM
Target Oncol; 2014 Dec; 9(4):339-47. PubMed ID: 24577626
[TBL] [Abstract] [Full Text] [Related]
19. FAM83D promotes cell proliferation and motility by downregulating tumor suppressor gene FBXW7.
Wang Z; Liu Y; Zhang P; Zhang W; Wang W; Curr K; Wei G; Mao JH
Oncotarget; 2013 Dec; 4(12):2476-86. PubMed ID: 24344117
[TBL] [Abstract] [Full Text] [Related]
20. PI3KCA mutation status is of limited prognostic relevance in ER-positive breast cancer patients treated with hormone therapy.
Cuorvo LV; Verderio P; Ciniselli CM; Girlando S; Decarli N; Leonardi E; Ferro A; Caldara A; Triolo R; Eccher C; Cantaloni C; Mauri F; Seckl M; Volante M; Buttitta F; Marchetti A; Silvia Q; Galligioni E; Palma PD; Barbareschi M
Virchows Arch; 2014 Jan; 464(1):85-93. PubMed ID: 24233241
[TBL] [Abstract] [Full Text] [Related]
[Next]
